Literature DB >> 16204472

Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.

Cleber E Teixeira1, Fernanda B M Priviero, R Clinton Webb.   

Abstract

Presumably, the vasorelaxant properties of phosphodiesterase type 5 (PDE5) inhibitors are similar in isolated blood vessels. We aimed to explore the mechanisms underlying the vasorelaxation induced by the selective PDE5 inhibitors sildenafil, vardenafil, and tadalafil in the rat aorta. Aortic rings were mounted in 5-ml organ baths, and concentration-response curves for PDE5 inhibitors (0.0001-10 microM) were constructed in phenylephrine (PE)-precontracted endothelium-intact and -denuded rings. Cyclic nucleotides were measured using enzyme immunoassay kits. Sildenafil, vardenafil, and tadalafil concentration dependently relaxed aortic rings and increased cGMP, but not cAMP, concentrations. Endothelium denudation caused marked rightward shifts in the curves to sildenafil (45-fold), tadalafil (21-fold), and vardenafil (251-fold). Maximal responses to sildenafil and tadalafil were substantially reduced (38 +/- 1% and 53 +/- 2%, respectively), whereas that evoked by vardenafil was not affected. Likewise, inhibition of NO synthase (N(omega)-nitro-L-arginine methyl ester, 100 microM), guanylyl cyclase (1H-[1,2,4]oxadiazolo [4,3,-a]quinoxalin-1-one, 10 microM), or scavenging of NO ([carboxy-PTIO (2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide), 100 microM]) caused similar attenuation of the vasorelaxations evoked by PDE5 inhibitors. Sildenafil, tadalafil, and vardenafil significantly potentiated relaxations mediated by glyceryl trinitrate (0.0001-3 microM; 8-13-fold) and atrial natriuretic peptide (0.1-100 nM; 2-3-fold). Contractions evoked by CaCl(2) (0.01-5 mM) in PE-treated rings were significantly reduced (26 +/- 4%) by vardenafil, but not sildenafil or tadalafil, whereas phorbol 12,13-dibutyrate-induced contractions were not affected. Ouabain, cyclopiazonic acid, and calyculin A failed to affect vasorelaxations induced by the PDE5 inhibitors. These results suggest that vardenafil, but not sildenafil or tadalafil, affects Ca(2+) handling in the rat aorta in addition to increasing cGMP levels through inhibition of PDE5 to cause relaxation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204472     DOI: 10.1124/jpet.105.092544

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.

Authors:  G Rossoni; B Manfredi; V De Gennaro Colonna; M Berti; M Guazzi; F Berti
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

2.  Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.

Authors:  Stuart D Katz
Journal:  Core Evid       Date:  2008-07-31

3.  TNF-alpha knockout mice have increased corpora cavernosa relaxation.

Authors:  Fernando S Carneiro; Lashon C Sturgis; Fernanda R C Giachini; Zidonia N Carneiro; Victor V Lima; Brandi M Wynne; Sebastian San Martin; Michael W Brands; Rita C Tostes; R Clinton Webb
Journal:  J Sex Med       Date:  2009-01       Impact factor: 3.802

4.  The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.

Authors:  T Radovits; T Bömicke; G Kökény; R Arif; S Loganathan; K Kécsán; S Korkmaz; E Barnucz; P Sandner; M Karck; G Szabó
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

5.  Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.

Authors:  Haroldo A Toque; Fernanda B M Priviero; Saiprasad M Zemse; Edson Antunes; Cleber E Teixeira; R Clinton Webb
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-10-15       Impact factor: 2.557

6.  Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension.

Authors:  Anna Sandqvist; Dan Henrohn; Hanna Egeröd; Mikael Hedeland; Lisa Wernroth; Ulf Bondesson; Jörn Schneede; Gerhard Wikström
Journal:  Eur J Clin Pharmacol       Date:  2015-08-05       Impact factor: 2.953

Review 7.  Pediatric pulmonary arterial hypertension.

Authors:  Dan-Chen Wu; Hong-Da Zhang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

8.  ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.

Authors:  Kyung-Hee Kim; Hyung-Kwan Kim; In-Chang Hwang; Seung-Pyo Lee; Hyun-Jai Cho; Hyun-Jae Kang; Yong-Jin Kim; Dae-Won Sohn
Journal:  Trials       Date:  2013-06-22       Impact factor: 2.279

9.  Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.

Authors:  Edibe Karasu-Minareci; Irem Hicran Ozbudak; Gulay Ozbilim; Gulay Sadan
Journal:  ScientificWorldJournal       Date:  2012-05-02

10.  cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation.

Authors:  Mariarosaria Bucci; Andreas Papapetropoulos; Valentina Vellecco; Zongmin Zhou; Altaany Zaid; Panagiotis Giannogonas; Anna Cantalupo; Sandeep Dhayade; Katia P Karalis; Rui Wang; Robert Feil; Giuseppe Cirino
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.